TOOLS FOR THE TRADE WEEKLY: Roche Diagnostics Day, VCYT MRD Coverage Secured & April NIH Outlays

Research evidence excerpt

TOOLS FOR THE TRADE WEEKLY: Roche Diagnostics Day, VCYT MRD Coverage Secured & April NIH Outlays

Life Science Tools & Diagnostics

May 17, 2026

TOOLS FOR THE TRADE WEEKLY: Roche Diagnostics Day, TICKER RTG PT % UP

A PP NA NAVCYT MRD Coverage Secured & April NIH Outlays

AVTR PP NA NA

BRKR OP $50 16.6%

The Wolfe Byte CAI OP $30 106.2%

After a busy few weeks of earnings, we recap share performance, key takeaways DHR OP $230 42.1%

from the past week, and highlight industry news and recent work. GH OP $120 26.4%

GRAL PP NA NA

ILMN OP $150 5.2%

STOCK PERFORMANCE: GROUP WAS DOWN ~6% LAST WEEK MRVI PP NA NA MTD PP NA NA

●Large Cap Tools: -5.12% Specialty Tools: -11.66% Dx: -6.20% Packaging & MYGN PP NA NA

Delivery: -3.12% NTRA OP $275 47.6% PACB PP NA NA

●Leaders: ILMN (+0.5% last week; +8.7% YTD) QGEN PP NA NA

●Laggards: PACB (-20.6% last week; -40.1% YTD); RGEN (-16.7% last week; RGEN OP $175 70.1%

-37.2% YTD); MYGN (-16.6% last week; -41.8% YTD) RVTY PP NA NA

SRT3-DE OP €275 34.2%

STVN OP $24 33.4%

Roche Dx Day Takeaways TEM PP NA NA

Sequencing...not a ton new here. Roche gave an indication for a workflow that does TMO OP $625 42.6% TWST OP $65 32.2%

target enrichment using duplex sequencing. This makes sense given what we came TXG PP NA NA

out of AGBT with and we are still of the belief that accuracy will primarily be between VCYT OP $50 29.9%

simplex and duplex sequencing. On TB testing... Roche plans to launch its new latent WAT OP $480 45.8%

WST PP NA NA

TB product next month and present data at the ESM Congress Verona in June - OP=Outperform, PP=Peer Perform,

the company has said that Positive Patient Agreement (PPA) and Negative Patient UP=Underperform, NR=Not Rated

Agreement (NPA) performance are "at parity" with the current standard of care for

latent TB testing.